• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

6.210 +0.640 (+11.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sagimet Biosciences Inc. - Series A Common Stock

< Previous 1 2 3 4 Next >
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
January 08, 2026
Via Chartmill
News headline image
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
January 08, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
December 18, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study ↗
October 24, 2025
Via Stocktwits
News headline image
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
December 17, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
December 10, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
November 20, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 13, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
November 10, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
October 24, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
October 22, 2025
 
Via Benzinga
News headline image
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
October 14, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
October 07, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
October 01, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
September 24, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
September 17, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
September 10, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
August 26, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Tops Q2 EPS Forecast ↗
August 13, 2025
Via The Motley Fool
News headline image
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 13, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 05, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
July 24, 2025
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
June 12, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
June 12, 2025
 
Via Benzinga
News headline image
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
June 09, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's pre-market session ↗
June 04, 2025
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps ↗
June 04, 2025
Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
June 04, 2025
 
Via Benzinga
News headline image
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
June 04, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap